March 05, 2026 EARNINGS CALL Q4 & ANNUAL 2025 OFER HAVIV | PRESIDENT & CEO

FORWARD LOOKING STATEMENT This presentation contains "forward-looking statements" relating to future events, and Evogene Ltd. (the “Company”), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the “PSLRA”) and other securities laws, as amended. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Such forward-looking statements may be identified by the use of such words as “believe”, “expect”, “anticipate”, “should”, “planned”, “estimated”, “intend” and “potential” or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, pipeline, as well as our capabilities and technology. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this presentation. Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, the aftermath of the recent war between Israel and each of (i) the terrorist groups, Hamas and Hezbollah, (ii) Iran, and (iii) other regional terrorist groups supported by Iran, and any destabilizations in Israel, neighboring territories or the Middle East region, and those described in greater detail in Evogene's Annual Report on Form 20-F and in other information Evogene files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading “Risk Factors”. Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions. The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene or the Company. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services. 2

Earnings Call Q4 2025 AGENDA By Ofer Haviv CEO Update By Yaron Eldad CFO Update Q&A

EVOGENE PIONEERSREAL-WORLD INNOVATION Using a proprietary generative AI engine, we design highly potent and novel small molecules, optimized across multiple-parameters, for the pharmaceutical and ag-chemical industries 4

GEN AI ENGINE Growing number of collaborations for diverse drug targets Strategic collaborations for ag-chemical development with proven results PIONEERING IN PHARMA REVOLUTIONIZING AG OUR STORY ChemPass AI™ - computational engine for the design & optimization of small molecules

NOVELTY - VAST CHEMICAL TERRITORIES based on a 38B-molecule chemical library, the engine designs novel compounds that are synthesizable and active, while accessing unexplored chemical space and creating new IP opportunities INTRODUCING CHEMPASS AI™: BREAKING CHEMICAL SPACE LIMITATION & MULTI-PARAMETER DESIGN HIGH-POTENCY - CHEMISTRY THAT PERFORMS AI-first designed molecules optimized through targeted experimental validation MULTI-PARAMETER OPTIMIZATIONmultiple-parameters optimized simultaneously, tailored to project-specific chemical, biological, and physical constraints, increasing probability of success 6

7 Technological Collaborations with GOOGLE CLOUDfrom generative models to autonomous discovery First Collaboration – FIRST-IN-CLASS FOUNDATION MODEL Successful completion of a proprietary generative AI model for novel molecular product candidates addressing multiple parameters, based on 38 billion molecular structures, delivered 90% precision compared to approx. 30% in traditional GPT models. Second Collaboration – ADVANCED AI AGENTS INTEGRATION Integration of AI agents into ChemPass AI™ using Google Cloud Vertex AI to decrease manual errors, accelerate design-make-test-analyze cycles, and enable scalable discovery of patentable small molecules with improved probability of development success for pharmaceutical and agricultural pipelines. Initiated Feb. 2026 “This expanded collaboration with Evogene demonstrates the power of integrating cutting-edge artificial intelligence into scientific research. By leveraging our technology to deploy advanced AI agents, we are enabling Evogene to automate and scale their complex discovery workflows. This foundation accelerates the speed and precision of identifying small molecules, further cementing Evogene's role as a leader in next-generation molecular design for the pharmaceutical and agricultural industries” BOAZ MAOZ, MANAGING DIRECTOR, GOOGLE CLOUD ISRAEL (10.02.2026)

Potency (Binding Affinity) Selectivity ML Models (QSAR) Scaffold Solubility Lipophilicity (LogP) Molecular Weight Hydrogen Bond Donors/Acceptors Chemical Stability Metabolic Stability Synthetic Accessibility IP/Novelty EVOGENE’S UNIQUE OFFERING – PROPRIETARY MOLECULAR DESIGN 8 A POWERFUL COMBINATION OF CAPABILITIES : Novel molecules are generated based on vast and diverse chemical territories Simultaneously optimized for multi-parameter requirements from day one Highly potent molecules optimized through targeted experimental validation

Literature search, data preprocessing and target modeling Target elucidation and biological interpretation HITSCREENING TARGETPREPROCESSING HIT-TO-LEAD Purchase hits and test activity and selectivity Synthesis of novel leads and validation Identify potential hits using PointHit Identify elaborated analogs using ActiveSearch Generate novel leads using LeadOptGPT CHEMPASS AI™ PARTNER / INTERNAL pipeline LEADOPTIMIZATION Purchase analogs and test activity and selectivity 9 Capturing the value of Chempass ai™ - our business model Through collaborations & in-house development PROPRIETARY PRODUCT CANDIDATE DEVELOPMENT STAGES

10 PHARMA DIVISION – Drugs EXTERNAL COLLABORATIONS Neutrophil-Derived Inflammatory Diseases Demyelination Disorders Lung Cancer Metabolic Disease EXTERNAL COLLABORATIONS Herbicides Herbicides INTERNAL PIPELINE Wheat Blotch EVOGENE - REAL-WORLD INNOVATION AG DIVISION* – Ag-Chemicals AG DIVISION* – Operations in this field are conducted through our subsidiary, AgPlenus.

11 High-potency molecules AI-first designed molecules optimized through targeted experimental validation Novel Chemical Space & IP Based on a 38B-molecule chemical library, the platform designs active novel compounds We design highly potent and novel small molecules, optimized across multiple-parameters, for the pharmaceutical and ag-chemical industries. MULTI-PARAMETER OPTIMIZATION Simultaneously optimizes chemical & biological parameters PIONEERING IN PHARMA Growing number of collaborations addressing diverse drug targets for the benefit of human health REVOLUTIONIZING AG Proven impact in Agriculture. Computational chemistry drives real-world agricultural impact Generating real-world innovation

Earnings Call Q3 2025 AGENDA By Ofer Haviv CEO Update By Yaron Eldad CFO Update Q&A unique

13 EVOGENE SUBSIDIARIES’ ACTIVITY

CFO UPDATE Financial Highlights

Earnings Call Q3 2025 AGENDA By Ofer Haviv CEO Update By Yaron Eldad CFO Update Q&A

THANK YOU